Fate Therapeutics, Inc.
NASDAQFATE enters the post-earnings session in an unusual position: a stock that rallied 81% over the past month is now being covered by shorts, not chased by them. Q1 results dropped this morning. EPS came in at -$0.26, beating the -$0.28 estimate. Revenue of $1.3M missed by roughly $0.25M — but for a clinical-stage iPSC therapy company still burning cash, the beat on the loss line…
FATE cost to borrow surges to 1.66% — up 192% in one week as short squeeze pressures mount.
Snapshot as of 22 Jun 2026
FATE enters the post-earnings session in an unusual position: a stock that rallied 81% over the past month is now being covered by shorts, not chased by them. Q1 results dropped this morning. EPS came in at -$0.26,…
Fate Therapeutics enters its May 14 earnings call riding an extraordinary week — the stock doubled on a regulatory catalyst while short sellers quietly trimmed positions and call buyers dominated the options…
Fate Therapeutics enters its May 14 earnings date with an uncomfortable combination: short interest ticking higher over the past week, borrow availability loosening, and a stock down nearly 10% in seven days to $1.24.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for FATE — free to start on ORTEX.
Sign up for free →Open FATE on ORTEX